Close
  Indian J Med Microbiol
 

Figure 2: Phase contrast microscopy images of ARPE-19 cells after 5 days exposure to bevacizumab shows healthy cells. (a) Untreated control ARPE-19 cells. (b) IgG-treated (1 mg/ml) control ARPE-19 cells. (c) ARPE-19 cells treated with 1 mg/ml bevacizumab. ×40

Figure 2: Phase contrast microscopy images of ARPE-19 cells after 5 days exposure to bevacizumab shows healthy cells. (a) Untreated control ARPE-19 cells. (b) IgG-treated (1 mg/ml) control ARPE-19 cells. (c) ARPE-19 cells treated with 1 mg/ml bevacizumab. ×40